This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
The pharmaceutical delivery components company reported fourth-quarter earnings in February of $18.9 million, or 56 cents a share, up from year-earlier earnings of $5.9 million, or 18 cents.
"Management indicated 2012 guidance reflects $0.08-0.15 [earnings per share] impact from [Crystal Zenith] products and other proprietary safety/administration devices," Jefferies analysts wrote in a Feb. 23 report. "However, WST acknowledged these sales depend on non- and pre-commercial customer use, which carries a higher risk that revenue may be lower than expected."
Forward Annual Dividend Yield: 1.8%
Rated "B+ (Buy)" by TheStreet Ratings: The company's fourth-quarter gross profit margin was about the same as it was the previous year.
West Pharmaceutical Services has weak liquidity. Its Quick Ratio is 0.98, which demonstrates a lack of ability to meet its short-term cash needs.
In the fourth quarter, stockholders' net worth increased 4.66% from the prior year.
TheStreet Ratings' price target is
-- Written by Alexandra Zendrian
>To contact the writer of this article, click here:
>To submit a news tip, send an email to:
>To follow the writer on Twitter, go to